AnaptysBio Inc - When Issued - April 2026(ANABV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | - | Perf Week | - |
| Market Cap | 1.91B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | - |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | -3.78% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -11.97% ($49.76) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 4.31% ($41.99) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 8.61% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -1.93% ($44.66) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -1.93% ($44.66) | Rel Volume | 0 | Prev Close | $43.8 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -1.93% ($44.66) | Avg Volume(3M) | 0.00M | Price | $43.8 |
| IPO | 2026/4/6 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🧬 This is an innovative US biotech company developing treatments for autoimmune and inflammatory diseases. Through a major restructuring in 2026, the company spun off its new drug development division and shifted its headquarters' focus to managing stable royalty revenue, pursuing a unique two-track valuation strategy.
Over the past 1 year, on the lower side
12% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
It ranks #97 of 598 in the industry
Based on market cap of $2B.
ANABV#97 AnaptysBio Inc - When Issued - April 2026 $2B PER - 
TRAX#97 First Tracks Biotherapeutics Inc $2B PER - 
REPL#98 Replimune Group Inc $2B PER - 
HRMY#99 Harmony Biosciences Holdings Inc $2B PER 10.7 
VIR#100 Vir Biotechnology Inc $2B PER - 
FAQ
What kind of company is ANABV?
ANABV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANABV?
The market cap of ANABV is approximately $1.9B, ranking 2,104 within its sector.
What is the 52-week high and low for ANABV?
ANABV has recorded a 52-week high of $49.76 and a low of $41.99.
